105 related articles for article (PubMed ID: 16178505)
1. Adverse effects of etoricoxib: other considerations.
Kim JA; Choi YS; Kim SH
Mayo Clin Proc; 2005 Sep; 80(9):1233-4; author reply 1234. PubMed ID: 16178505
[No Abstract] [Full Text] [Related]
2. [By what means does the rheumatic patient with gastrointestinal risks fare best?].
Einecke D
MMW Fortschr Med; 2007 Mar; 149(10):18. PubMed ID: 17408040
[No Abstract] [Full Text] [Related]
3. Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial.
Baraf HS; Fuentealba C; Greenwald M; Brzezicki J; O'Brien K; Soffer B; Polis A; Bird S; Kaur A; Curtis SP;
J Rheumatol; 2007 Feb; 34(2):408-20. PubMed ID: 17304660
[TBL] [Abstract][Full Text] [Related]
4. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Laine L; Curtis SP; Cryer B; Kaur A; Cannon CP;
Lancet; 2007 Feb; 369(9560):465-73. PubMed ID: 17292766
[TBL] [Abstract][Full Text] [Related]
5. Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).
Krueger K; Lino L; Dore R; Radominski S; Zhang Y; Kaur A; Simpson R; Curtis S
Ann Rheum Dis; 2008 Mar; 67(3):315-22. PubMed ID: 17965424
[TBL] [Abstract][Full Text] [Related]
6. Dose proportionality of oral etoricoxib, a highly selective cyclooxygenase-2 inhibitor, in healthy volunteers.
Agrawal NG; Porras AG; Matthews CZ; Woolf EJ; Miller JL; Mukhopadhyay S; Neu DC; Gottesdiener KM
J Clin Pharmacol; 2001 Oct; 41(10):1106-10. PubMed ID: 11583479
[TBL] [Abstract][Full Text] [Related]
7. The cardiovascular risks of etoricoxib (Arcoxia).
Sasich LD; Barasain MA; Al Kudsi MA
Ann Saudi Med; 2008; 28(2):141-2. PubMed ID: 18398284
[No Abstract] [Full Text] [Related]
8. Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis.
Reginster JY; Malmstrom K; Mehta A; Bergman G; Ko AT; Curtis SP; Reicin AS
Ann Rheum Dis; 2007 Jul; 66(7):945-51. PubMed ID: 17142385
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study).
Combe B; Swergold G; McLay J; McCarthy T; Zerbini C; Emery P; Connors L; Kaur A; Curtis S; Laine L; Cannon CP
Rheumatology (Oxford); 2009 Apr; 48(4):425-32. PubMed ID: 19223284
[TBL] [Abstract][Full Text] [Related]
10. Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
Prescrire Int; 2007 Dec; 16(92):223-7. PubMed ID: 18084859
[TBL] [Abstract][Full Text] [Related]
11. A world without Vioxx: to COX-2 or not to COX-2?
Simon LS; Strand V
Cleve Clin J Med; 2004 Nov; 71(11):849-50, 852, 854 passim. PubMed ID: 15570734
[No Abstract] [Full Text] [Related]
12. Asthmatic reaction induced by Etoricoxib in a patient with aspirin-sensitive asthma.
Koschel D; Cardoso C; Leucht V; Hoffken G
Allergy; 2008 Aug; 63(8):1093-4. PubMed ID: 18691317
[No Abstract] [Full Text] [Related]
13. Safety of etoricoxib in patients with reactions to NSAIDs.
Quercia O; Emiliani F; Foschi FG; Stefanini GF
J Investig Allergol Clin Immunol; 2008; 18(3):163-7. PubMed ID: 18564626
[TBL] [Abstract][Full Text] [Related]
14. Lack of effect of antacids on single-dose pharmacokinetics of etoricoxib.
Schwartz JI; Agrawal NG; Kher UA; DeSmet M; Cavanaugh PF; Guillaume M; Ebel DL; Merschman SA; Wagner JA
J Clin Pharmacol; 2007 Oct; 47(10):1342-6. PubMed ID: 17656618
[No Abstract] [Full Text] [Related]
15. Safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease.
El Miedany Y; Youssef S; Ahmed I; El Gaafary M
Ann Allergy Asthma Immunol; 2006 Jul; 97(1):105-9. PubMed ID: 16892790
[TBL] [Abstract][Full Text] [Related]
16. Rofecoxib, Merck, and the FDA.
Wolfe MM
N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625749
[No Abstract] [Full Text] [Related]
17. Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program.
Krum H; Curtis SP; Kaur A; Wang H; Smugar SS; Weir MR; Laine L; Brater DC; Cannon CP
Eur J Heart Fail; 2009 Jun; 11(6):542-50. PubMed ID: 19380329
[TBL] [Abstract][Full Text] [Related]
18. Report of specific cardiovascular outcomes of the ADVANTAGE trial.
Braunstein N; Polis A
Ann Intern Med; 2005 Jul; 143(2):158-9. PubMed ID: 15968005
[No Abstract] [Full Text] [Related]
19. Life after Vioxx: the clinical implications.
Fortun PJ; Hawkey CJ
Hosp Med; 2005 May; 66(5):264-7. PubMed ID: 15920854
[No Abstract] [Full Text] [Related]
20. Single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man.
Agrawal NG; Porras AG; Matthews CZ; Rose MJ; Woolf EJ; Musser BJ; Dynder AL; Mazina KE; Lasseter KC; Hunt TL; Schwartz JI; McCrea JB; Gottesdiener KM
J Clin Pharmacol; 2003 Mar; 43(3):268-76. PubMed ID: 12638395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
